Research Topic

Targeted Therapies for Glioblastoma: A Critical Appraisal

About this Research Topic

Glioblastoma multiforme (GBM) is an aggressive and fatal disease with less than 2% of patients surviving 5 years without tumor recurrence after initial diagnosis and treatment. Concerted efforts have been made towards drug development and novel therapeutic approaches for glioblastoma, yet the progress is limited and the prognosis for the patients with GBM remains poor. Inherent or acquired resistance to available therapies, regional and heterogeneous blood-glioma barrier, and the population of stem-like cells within glioblastoma present challenges that are being aggressively addressed. In particular, advances have been made in understanding the molecular biology of glioblastoma, resulting in a number of new treatment modalities, including tyrosine kinase inhibitors, angiogenesis inhibitors, gene-, viro- and immuno-therapies. In addition, the emphasis has been to define sensitizing strategies that may potentiate efficacy of existing chemo- or radio-therapies.

Induction of DNA damage and deregulation of DNA repair pathways is the hallmark of current approaches of chemo- and radio-therapy, and gene expression or mutation profile has been in focus to intense analyses aimed at defining new therapeutic targets. A focused (or whole genome) siRNA screens have been instrumental in identification of several druggable targets. Similarly, multifaceted approach to measure DNA repair capacity in tumor cells has been developed and may have wide clinical implications especially to determine sensitivity to genotoxic drugs. Bi-allelic mutation in IDH1 found in secondary GBM cause deficit of NAD+, trigger production of onco-metabolite 2-hydroxy glutarate now have been found associated with compromised homologous recombination ability and synthetic lethality of PARP inhibitors. However, evidence from more recent publications indicate that PARP inhibition may not be suitable for IDH mutants especially in combination with alkylating agents. Prospective discussion of these relatively newer findings may shape the future directions for biomarker strategies for chemo- and radio-sensitizers.

This Frontiers Research Topic shall provide a platform for active discussion and summarize current knowledge of blood-brain barrier, cancer metabolism, cell signaling and genetic, epigenetic regulation of drug sensitivity/resistance, and offer new perspectives on developing novel therapeutic approaches and biomarkers for glioblastoma. We welcome high-quality original research articles, brief reports, as well as opinion, hypothesis, and review articles, and especially encourage submissions from early-career scientists.


Keywords: GBM, Blood-brain barrier, drug resistance, sensitizing therapies, DNA damage, onco-metabolites


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Glioblastoma multiforme (GBM) is an aggressive and fatal disease with less than 2% of patients surviving 5 years without tumor recurrence after initial diagnosis and treatment. Concerted efforts have been made towards drug development and novel therapeutic approaches for glioblastoma, yet the progress is limited and the prognosis for the patients with GBM remains poor. Inherent or acquired resistance to available therapies, regional and heterogeneous blood-glioma barrier, and the population of stem-like cells within glioblastoma present challenges that are being aggressively addressed. In particular, advances have been made in understanding the molecular biology of glioblastoma, resulting in a number of new treatment modalities, including tyrosine kinase inhibitors, angiogenesis inhibitors, gene-, viro- and immuno-therapies. In addition, the emphasis has been to define sensitizing strategies that may potentiate efficacy of existing chemo- or radio-therapies.

Induction of DNA damage and deregulation of DNA repair pathways is the hallmark of current approaches of chemo- and radio-therapy, and gene expression or mutation profile has been in focus to intense analyses aimed at defining new therapeutic targets. A focused (or whole genome) siRNA screens have been instrumental in identification of several druggable targets. Similarly, multifaceted approach to measure DNA repair capacity in tumor cells has been developed and may have wide clinical implications especially to determine sensitivity to genotoxic drugs. Bi-allelic mutation in IDH1 found in secondary GBM cause deficit of NAD+, trigger production of onco-metabolite 2-hydroxy glutarate now have been found associated with compromised homologous recombination ability and synthetic lethality of PARP inhibitors. However, evidence from more recent publications indicate that PARP inhibition may not be suitable for IDH mutants especially in combination with alkylating agents. Prospective discussion of these relatively newer findings may shape the future directions for biomarker strategies for chemo- and radio-sensitizers.

This Frontiers Research Topic shall provide a platform for active discussion and summarize current knowledge of blood-brain barrier, cancer metabolism, cell signaling and genetic, epigenetic regulation of drug sensitivity/resistance, and offer new perspectives on developing novel therapeutic approaches and biomarkers for glioblastoma. We welcome high-quality original research articles, brief reports, as well as opinion, hypothesis, and review articles, and especially encourage submissions from early-career scientists.


Keywords: GBM, Blood-brain barrier, drug resistance, sensitizing therapies, DNA damage, onco-metabolites


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

01 March 2018 Abstract
01 August 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

01 March 2018 Abstract
01 August 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top